Background
Background Heroin-assisted Heroin-assisted treatment has been found to be effective treatment has been found to be effective for people with severe opioid dependence for people with severe opioid dependence who are not interested in or do poorly on who are not interested in or do poorly on methadone maintenance. methadone maintenance.
Aims Aims To study heroin-assisted
To study heroin-assisted treatment in people on methadone who treatment in people on methadone who continue intravenous heroin and in those continue intravenous heroin and in those who are heroin dependent but currently who are heroin dependent but currently not in treatment. not in treatment.
Method Method In an open-label multicentre
In an open-label multicentre randomised controlled trial,1015 people randomised controlled trial,1015 people with heroin dependence received a with heroin dependence received a variable dose of injectable heroin ( variable dose of injectable heroin (n n¼515) 515) or oral methadone ( or oral methadone (n n¼500) for12 500) for12 months.Two response criteria, months.Two response criteria, improvement of physical and/or mental improvement of physical and/or mental health and decrease inillicitdrug use, were health and decreaseinillicitdrug use, were evaluated in an intent-to-treat analysis. evaluated in an intent-to-treat analysis.
Results
Results Retention was higher in the Retention was higher in the heroin (67.2%) than in the methadone heroin (67.2%) than in the methadone group (40.0%) and the heroin group group (40.0%) and the heroin group showed a significantly greater response on showed a significantly greater response on both primary outcome measures.More both primary outcome measures.More serious adverse events were found in the serious adverse events were found in the heroin group, and were mainly associated heroin group, and were mainly associated with intravenous use. with intravenous use.
Conclusions Conclusions Heroin-assisted
Heroin-assisted treatment is more effective for people treatment is more effective for people with opioid dependence who continue with opioid dependence who continue intravenous heroin while on methadone intravenous heroin while on methadone maintenance or who are not enrolled in maintenance or who are not enrolled in treatment.Despite a higher risk, it should treatment.Despite a higher risk, it should be considered for treatment resistance be considered for treatment resistance under medical supervision. under medical supervision.
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Germany has an estimated 150 000 people Germany has an estimated 150 000 people with opioid dependence, mainly heroin dewith opioid dependence, mainly heroin dependence, among a population of 80 milpendence, among a population of 80 million (Buhringer lion (Bü hringer et al et al, 1997) . Less than half , 1997). Less than half (50 000-60 000) at any given time are on (50 000-60 000) at any given time are on opioid maintenance treatment. None the opioid maintenance treatment. None the less, the mortality rate only decreased less, the mortality rate only decreased slightly after the widespread introduction slightly after the widespread introduction of maintenance treatment in the early of maintenance treatment in the early 1990s (Raschke 1990s (Raschke et al et al, 2000) , which is in , 2000), which is in accordance with other long-term followaccordance with other long-term followup studies (Rathod up studies (Rathod et al et al, 2005) . This , 2005) . This opened the discussion for modification of opened the discussion for modification of maintenance treatment, especially for maintenance treatment, especially for people who either dropped out or who people who either dropped out or who continued treatment but also illicit opioid continued treatment but also illicit opioid use. use.
A large ( A large (n n¼1969) cohort study was 1969) cohort study was initiated in Switzerland in 1994, and initiated in Switzerland in 1994, and ascertained the feasibility, safety and potenascertained the feasibility, safety and potential efficacy of offering injectable heroin to tial efficacy of offering injectable heroin to people with dependence who were not repeople with dependence who were not responding sufficiently to maintenance treatsponding sufficiently to maintenance treatment (Rehm ment (Rehm et al et al, 2001) . The study , 2001). The study showed a high retention rate (70% after showed a high retention rate (70% after 12 months) as well as positive effects with 12 months) as well as positive effects with respect to illegal drug use, physical and respect to illegal drug use, physical and mental health and social outcomes. Howmental health and social outcomes. However, assessment of the Swiss trial by the ever, assessment of the Swiss trial by the World Health Organization was unable to World Health Organization was unable to determine if the positive effects were a redetermine if the positive effects were a result of the prescription of heroin, the extensult of the prescription of heroin, the extensive psychosocial counselling and care, or sive psychosocial counselling and care, or the combination of both (Ali the combination of both (Ali et al et al, 1999) . , 1999). A small randomised controlled trial A small randomised controlled trial ( (n n¼51) comparing injectable heroin with a 51) comparing injectable heroin with a standard treatment (mainly methadone standard treatment (mainly methadone maintenance) showed significantly better maintenance) showed significantly better functioning in those receiving heroin after functioning in those receiving heroin after 6 months (Perneger 6 months (Perneger et al et al, 1998) . However, , 1998). However, those people also received additional, those people also received additional, mandatory psychosocial care, which may mandatory psychosocial care, which may have influenced the results. have influenced the results.
In 1998 two randomised controlled In 1998 two randomised controlled trials in The Netherlands assessed the effectrials in The Netherlands assessed the effectiveness of the co-prescription of inhalable tiveness of the co-prescription of inhalable ( (n n¼375) and injectable ( 375) and injectable (n n¼174) heroin in 174) heroin in people with opioid dependence and chronic people with opioid dependence and chronic resistance to methadone treatment. Results resistance to methadone treatment. Results showed that heroin-assisted treatment was showed that heroin-assisted treatment was feasible, more effective and probably as feasible, more effective and probably as safe as methadone alone in reducing physisafe as methadone alone in reducing physical, mental and social problems (van den cal, mental and social problems (van den Brink Brink et al et al, 2003; Blanken , 2003; Blanken et al et al, 2005) . , 2005). Co-prescription of heroin was cost-effective Co-prescription of heroin was cost-effective compared with methadone treatment alone compared with methadone treatment alone (Dijkgraaf (Dijkgraaf et al et al, 2005) . A limitation of , 2005). A limitation of these trials was that psychosocial treatthese trials was that psychosocial treatments were not standardised and were unments were not standardised and were uncontrolled. Furthermore, the larger of the controlled. Furthermore, the larger of the two trials used inhalable heroin, which is two trials used inhalable heroin, which is used by the majority (75-90%) of street used by the majority (75-90%) of street heroin users in The Netherlands, but not heroin users in The Netherlands, but not in Germany. in Germany.
A recent Cochrane review (Ferri A recent Cochrane review (Ferri et al et al, , 2005) found that the Swiss and Dutch stu-2005) found that the Swiss and Dutch studies do not allow a definite conclusion to dies do not allow a definite conclusion to be drawn about the overall effectiveness be drawn about the overall effectiveness of heroin prescription because of a lack of of heroin prescription because of a lack of comparability. We therefore examined the comparability. We therefore examined the effectiveness of medically prescribed and effectiveness of medically prescribed and supervised heroin injection in an open-label supervised heroin injection in an open-label randomised controlled trial in two groups randomised controlled trial in two groups of people with heroin dependence: those of people with heroin dependence: those not responding sufficiently to methadone not responding sufficiently to methadone maintenance treatment and those currently maintenance treatment and those currently not in substance misuse treatment. To connot in substance misuse treatment. To control for the impact of psychosocial treattrol for the impact of psychosocial treatment, participants in each group were ment, participants in each group were randomised to one of two types of psychorandomised to one of two types of psychosocial care. social care.
METHOD METHOD

Study design Study design
After screening more than 2000 people After screening more than 2000 people with heroin dependence, a total of 1032 with heroin dependence, a total of 1032 consenting participants were randomised consenting participants were randomised between March 2002 and December 2003 between March 2002 and December 2003 in seven treatment centres (Hamburg, 401 in seven treatment centres (Hamburg, 401 participants; Frankfurt, 191; Hanover, participants; Frankfurt, 191; Hanover, 132; Bonn, 100; Cologne, 100; Munich, 132; Bonn, 100; Cologne, 100; Munich, 60; Karlsruhe, 48) . Participants were from 60; Karlsruhe, 48). Participants were from two target groups: (a) people with heroin two target groups: (a) people with heroin dependence who were insufficiently redependence who were insufficiently responding to treatment owing to continuous sponding to treatment owing to continuous intravenous heroin use ( intravenous heroin use (n n¼492); and (b) 492); and (b) people with heroin dependence who were people with heroin dependence who were not in treatment in the previous 6 months not in treatment in the previous 6 months ( (n n¼540). Participants from each target 540). Participants from each target group were randomised into four subgroup were randomised into four subgroups according to the type of medication groups according to the type of medication and the type of psychosocial care (Fig. 1) , and the type of psychosocial care (Fig. 1) , resulting in a 2 resulting in a 26 62 26 62 design and eight 2 design and eight separate groups. Of the 811 people lost beseparate groups. Of the 811 people lost between screening and baseline, 106 (13.1%) tween screening and baseline, 106 (13.1%) did not meet inclusion criteria and the did not meet inclusion criteria and the 5 5 5 5 others did not attend for examination. Of others did not attend for examination. Of the 240 people lost between baseline and the 240 people lost between baseline and randomisation, 1 died (0.4%), 14 (5.8%) randomisation, 1 died (0.4%), 14 (5.8%) were rejected by the expert panels for not were rejected by the expert panels for not meeting study inclusion criteria and the rest meeting study inclusion criteria and the rest did not complete the baseline examination did not complete the baseline examination or attend for randomisation. Seventeen or attend for randomisation. Seventeen patients, 5 previously on methadone and patients, 5 previously on methadone and 12 not in treatment, were excluded from 12 not in treatment, were excluded from analysis because they withdrew their conanalysis because they withdrew their consent after randomisation without initiating sent after randomisation without initiating study treatment ( study treatment (n n¼8), because they did 8), because they did not have an independent baseline interview not have an independent baseline interview prior to randomisation ( prior to randomisation (n n¼8), or both 8), or both ( (n n¼1), leaving 1015 patients in the intent-1), leaving 1015 patients in the intentto-treat analysis ( to-treat analysis (n n¼487 treatment failure, 487 treatment failure, n n¼528 not in treatment).
528 not in treatment). After giving consent, participants were After giving consent, participants were given an extensive baseline examination. given an extensive baseline examination. Inclusion criteria were then presented to a Inclusion criteria were then presented to a local independent expert committee before local independent expert committee before a final decision for inclusion was made. a final decision for inclusion was made. Then a second consent was necessary Then a second consent was necessary before randomisation. Randomisation took before randomisation. Randomisation took place separately for each target group place separately for each target group (methadone treatment failure and not in (methadone treatment failure and not in treatment), and treatment allocation was treatment), and treatment allocation was performed using sealed and consecutively performed using sealed and consecutively numbered envelopes at each study site. numbered envelopes at each study site.
Treatment duration was 12 months. Treatment duration was 12 months. Treatment in the intervention group conTreatment in the intervention group consisted of an individually adjusted dose of sisted of an individually adjusted dose of injectable heroin that was self-administered injectable heroin that was self-administered in an out-patient setting under direct in an out-patient setting under direct supervision of medical staff, maximally supervision of medical staff, maximally three times a day, 7 days a week, with a three times a day, 7 days a week, with a maximum single dose of 400 mg and a maximum single dose of 400 mg and a maximum daily dose of 1000 mg (none to maximum daily dose of 1000 mg (none to take home). Up to 60 mg of methadone take home). Up to 60 mg of methadone could also be given for take-home nightcould also be given for take-home nighttime use to suppress withdrawal. Treatment time use to suppress withdrawal. Treatment in the control group consisted of a in the control group consisted of a minimum daily dose of 60 mg methadone, minimum daily dose of 60 mg methadone, which could be individually adjusted acwhich could be individually adjusted according to clinical judgement. Participants cording to clinical judgement. Participants within both groups were randomised to within both groups were randomised to either group psychoeducation plus individeither group psychoeducation plus individual counselling according to Farnbacher ual counselling according to Farnbacher et et al al (2002) , or case management and motiva-(2002), or case management and motivational interviewing according to Oliva tional interviewing according to Oliva et al et al (2001) . Each of these interventions has (2001) . Each of these interventions has been described in manuals, and training of been described in manuals, and training of all therapists was conducted prior to the all therapists was conducted prior to the study to minimise site differences. The type study to minimise site differences. The type of psychosocial care was similar with of psychosocial care was similar with respect to average intensity of contact, but respect to average intensity of contact, but there was more individual flexibility in the there was more individual flexibility in the case management group than with the more case management group than with the more standardised psychosocial care in the standardised psychosocial care in the psychoeducation group. psychoeducation group.
Study population Study population
Inclusion criteria were 23 years old or Inclusion criteria were 23 years old or greater and an ICD-10 diagnosis of opioid greater and an ICD-10 diagnosis of opioid dependence of at least 5 years' duration dependence of at least 5 years' duration (World Health Organization, 1993) . (World Health Organization, 1993) . Furthermore, eligibility criteria for the Furthermore, eligibility criteria for the group with methadone treatment failure ingroup with methadone treatment failure included continued intravenous use of street cluded continued intravenous use of street heroin (confirmed by urine testing) despite heroin (confirmed by urine testing) despite ongoing maintenance treatment of at least ongoing maintenance treatment of at least 6 months, whereas for the not in treatment 6 months, whereas for the not in treatment group they included regular intravenous use group they included regular intravenous use of street heroin (confirmed by urine testing) of street heroin (confirmed by urine testing) and confirmed participation in previous and confirmed participation in previous drug treatment. Participants needed to have drug treatment. Participants needed to have poor physical and/or mental health, with at poor physical and/or mental health, with at least 13 symptoms on the Opiate Treatment least 13 symptoms on the Opiate Treatment Index (OTI) Health Scale (Darke Index (OTI) Health Scale (Darke et al et al, , 1991 (Darke et al et al, , , 1992 and/or at least 60 points 1991, 1992) and/or at least 60 points (standardised T-score) on the Global (standardised T-score) on the Global Severity Index of the Symptom Check-List Severity Index of the Symptom Check-List (SCL-90-R; Derogatis, 1983) . (SCL-90-R; Derogatis, 1983) .
People with a pending jail sentence, People with a pending jail sentence, those who had been abstinent for 2 or more those who had been abstinent for 2 or more months in the past 12 months and those months in the past 12 months and those 5 6 5 6 AUTHOR'S PROOF AUTHOR'S PROOF with a severe physical disorder such as with a severe physical disorder such as renal renal or hepatic failure, clinically significant or hepatic failure, clinically significant cardicardiac arrhythmias or chronic obstructive pulac arrhythmias or chronic obstructive pulmonary disease were excluded, as were monary disease were excluded, as were pregnant or breast-feeding women. pregnant or breast-feeding women.
Assessments and statistical Assessments and statistical analyses analyses
Baseline assessments were completed by Baseline assessments were completed by study physicians and independent research study physicians and independent research assistants before a decision was made on assistants before a decision was made on randomisation. Potential study inclusion randomisation. Potential study inclusion was based on physician assessment only was based on physician assessment only but had to be confirmed by an independent but had to be confirmed by an independent panel of experts after baseline assessment, panel of experts after baseline assessment, which delayed initiation of treatment for which delayed initiation of treatment for an average of 31 days. Study physicians an average of 31 days. Study physicians re-assessed people who were approved for re-assessed people who were approved for randomisation at initiation of treatment, randomisation at initiation of treatment, and at 1, 3, 6 and 12 months. Independent and at 1, 3, 6 and 12 months. Independent assessment by research assistants was perassessment by research assistants was performed at 6 and 12 months. formed at 6 and 12 months.
Assessment by the study physician Assessment by the study physician included application of the OTI and SCLincluded application of the OTI and SCL-90-R, the composite international diagnos-90-R, the composite international diagnostic interview (CIDI; World Health Orgtic interview (CIDI; World Health Organization, 1990), and the severity of anization, 1990), and the severity of withdrawal scale (SOWS; Gossop, 1990) , withdrawal scale (SOWS; Gossop, 1990) , and a comprehensive physical examination, and a comprehensive physical examination, including electrocardiography, laboratory including electrocardiography, laboratory examinations, echocardiography, abdominal examinations, echocardiography, abdominal ultrasonography, urine and hair analyses, ultrasonography, urine and hair analyses, as well as all serious adverse events. All as well as all serious adverse events. All serious adverse events, defined according serious adverse events, defined according to guidelines E2A and E6 of the Internato guidelines E2A and E6 of the International Conference on Harmonisation of tional Conference on Harmonisation of Technical Registration for Recognition of Technical Registration for Recognition of Pharmaceuticals for Human Use (ICH; Pharmaceuticals for Human Use (ICH; http://www.ich.org) were reported to a http://www.ich.org) were reported to a safety board, which consisted of three safety board, which consisted of three independent clinicians, who evaluated all independent clinicians, who evaluated all adverse events with respect to safety of adverse events with respect to safety of the study treatment. The assessment by the study treatment. The assessment by independent research assistants included independent research assistants included administration of the European version of administration of the European version of the Addiction Severity Index (EuropASI; the Addiction Severity Index (EuropASI; Kokkevi & Hartgers, 1995) , and gathering Kokkevi & Hartgers, 1995) , and gathering data on criminal behaviour and on subjective data on criminal behaviour and on subjective aspects of treatment. aspects of treatment.
In the intent-to-treat analysis, all those In the intent-to-treat analysis, all those randomised were assessed regardless of randomised were assessed regardless of treatment retention. Data from the baseline treatment retention. Data from the baseline and 12-month assessments were used for and 12-month assessments were used for analysis of the primary outcome measures; analysis of the primary outcome measures; the last-observation-carried-forward (LOCF) the last-observation-carried-forward (LOCF) procedure from data at 6 months was used procedure from data at 6 months was used if data at 12 months were missing. If no if data at 12 months were missing. If no data were available for 6 and 12 months, data were available for 6 and 12 months, the outcome was coded according to a the outcome was coded according to a worst-case analysis (i.e. as a responder in worst-case analysis (i.e. as a responder in the methadone group and a non-responder the methadone group and a non-responder in the heroin group). in the heroin group).
Two prespecified dichotomous, multiTwo prespecified dichotomous, multidomain primary outcome measures were domain primary outcome measures were used. For the primary outcome measure used. For the primary outcome measure on health, participants were considered on health, participants were considered responders if they showed at least a 20% responders if they showed at least a 20% improvement and at least 4 points on the improvement and at least 4 points on the OTI Health Scale (physical health) and/or OTI Health Scale (physical health) and/or at least a 20% improvement in the GSI at least a 20% improvement in the GSI (mental health), without a deterioration of (mental health), without a deterioration of more than 20% in the other area of health. more than 20% in the other area of health. For the second primary outcome measure, For the second primary outcome measure, people were considered responders if they people were considered responders if they showed a reduction in the use of street showed a reduction in the use of street heroin with at least 3 of 5 urine samples heroin with at least 3 of 5 urine samples negative for the drug in the month prior negative for the drug in the month prior to the 12-month assessment and no increase to the 12-month assessment and no increase in cocaine use (hair analysis). If less than 3 in cocaine use (hair analysis). If less than 3 urine samples or no hair was available at 12 urine samples or no hair was available at 12 months, data from urine or hair testing at 6 months, data from urine or hair testing at 6 months were used (LOCF). If these were months were used (LOCF). If these were also not available, data were replaced by also not available, data were replaced by self-reported data from the EuropASI. self-reported data from the EuropASI. When self-reported data were used, reWhen self-reported data were used, response was defined as a 60% decrease in sponse was defined as a 60% decrease in the number of days with street heroin use the number of days with street heroin use and no more than 2 days' increase in and no more than 2 days' increase in cocaine use during the past month. To cocaine use during the past month. To distinguish between prescribed and illicit distinguish between prescribed and illicit heroin, urine samples were tested for heroin, urine samples were tested for papaverine and acetylcodeine, which are papaverine and acetylcodeine, which are common impurities found in street heroin common impurities found in street heroin . A four-factorial logistic regression A four-factorial logistic regression model was used to assess the effectiveness model was used to assess the effectiveness of heroin-assisted treatment compared with of heroin-assisted treatment compared with methadone, controlling for the effect of the methadone, controlling for the effect of the target group (methadone treatment failure target group (methadone treatment failure v. v. not in treatment), the psychosocial internot in treatment), the psychosocial intervention (psychoeducation vention (psychoeducation v.
v. case managecase management) and study site (likelihood ratio test). ment) and study site (likelihood ratio test). Using a test on interaction between primary Using a test on interaction between primary outcome and target group (methadone outcome and target group (methadone treatment failure or not in treatment), we treatment failure or not in treatment), we assessed whether the effect of pharmacoassessed whether the effect of pharmacological treatment was independent of the logical treatment was independent of the target group. The hypothesis would be target group. The hypothesis would be confirmed if the logistic regression model confirmed if the logistic regression model showed superiority of heroin over methshowed superiority of heroin over methadone for both primary outcome measures adone for both primary outcome measures ('health' and 'illegal drug use') at the 5% ('health' and 'illegal drug use') at the 5% significance level. Statistical analyses were significance level. Statistical analyses were performed using SPSS versions 10 and 11 performed using SPSS versions 10 and 11 for Windows. for Windows.
Calculations of sample size were based Calculations of sample size were based on an estimated response rate of 30% in on an estimated response rate of 30% in the methadone group and 50% in the the methadone group and 50% in the heroin group for each primary outcome heroin group for each primary outcome measure. Based on a one-tailed significance measure. Based on a one-tailed significance criterion of 0.025 ( criterion of 0.025 (a a) and a ) and a b b of 0.90 for of 0.90 for each primary outcome measure, the total each primary outcome measure, the total power remained 80% (0.9*0.9) for the power remained 80% (0.9*0.9) for the study to yield a statistically significant restudy to yield a statistically significant result. Assuming that 10% of the methadone sult. Assuming that 10% of the methadone group and 5% of the heroin group would group and 5% of the heroin group would not be reached for assessment at 6 or 12 not be reached for assessment at 6 or 12 months, and therefore according to the months, and therefore according to the worst case definition would be considered worst case definition would be considered responders and non-responders respecresponders and non-responders respectively, the reduced effect size led to a tively, the reduced effect size led to a minimum sample size of 482 for each treatminimum sample size of 482 for each treatment group (heroin ment group (heroin v.
v. methadone). methadone). 
RESULTS RESULTS
Sample characteristics Sample characteristics
Treatment effectiveness Treatment effectiveness
In the intent-to-treat analysis, the heroin In the intent-to-treat analysis, the heroin treatment group showed a significantly treatment group showed a significantly greater response than the methadone treatgreater response than the methadone treatment group with respect to both primary ment group with respect to both primary outcome measures (Table 2) . outcome measures (Table 2) . With respect to the primary outcome With respect to the primary outcome measure 'health', logistic regression analymeasure 'health', logistic regression analysis showed no effect of target group (methasis showed no effect of target group (methadone treatment failure done treatment failure v.
v. not in treatment; not in treatment; P P¼0.320), study centre ( 0.320), study centre (P P¼0.143) and type 0.143) and type of psychosocial intervention (psychoof psychosocial intervention (psychoeducation education v.
v. case management; case management; P P¼0.269). 0.269). In addition, no interaction was found In addition, no interaction was found between medication group and target group between medication group and target group ( (P P¼0.544). After adjustment for target 0.544). After adjustment for target group, study centre and type of psychosocial group, study centre and type of psychosocial care, the main effect of medication group care, the main effect of medication group on the primary outcome measure 'health' on the primary outcome measure 'health' remained significant (OR remained significant (OR¼1.54, 95% CI 1.54, 95% CI 1.02-2.34, 1.02-2.34, P P¼0.042). 0.042). With respect to the primary outcome With respect to the primary outcome measure 'illicit drug use', a significant effect measure 'illicit drug use', a significant effect of study centre was found ( of study centre was found (P P¼0.002), 0.002), indicating that response rates were not indicating that response rates were not 5 8 5 8 AUTHOR'S PROOF AUTHOR'S PROOF (F2), affective (F3), neurotic (F4) or behavioural (F5) disorder. 2. One participant did not meet criteria for 6-month maintenance treatment in independent assessment. 2. One participant did not meet criteria for 6-month maintenance treatment in independent assessment. homogenous across centres. Target group homogenous across centres. Target group ( (P P¼0.228) and type of psychosocial care 0.228) and type of psychosocial care ( (P P¼0.369) showed no significant effect. 0.369) showed no significant effect. Furthermore, no interaction was found beFurthermore, no interaction was found between medication effect and target group tween medication effect and target group ( (P P¼0.840). After adjustment for target 0.840). After adjustment for target group, study centre and type of psychogroup, study centre and type of psychosocial care, the main effect of medication social care, the main effect of medication group on the primary outcome measure group on the primary outcome measure 'illicit drug use' remained significant 'illicit drug use' remained significant (OR (OR¼1.91, 95% CI 1.30-2.79, 1.91, 95% CI 1.30-2.79, P P¼0.001). 0.001). Of the 1015 patients included in the Of the 1015 patients included in the intent-to-treat analysis, 546 (346 in the intent-to-treat analysis, 546 (346 in the heroin group and 200 in the methadone heroin group and 200 in the methadone group) completed the study as defined per group) completed the study as defined per protocol. In those 546 participants the reprotocol. In those 546 participants the response rates were slightly higher than in sponse rates were slightly higher than in the intent-to-treat analysis, but the heroin the intent-to-treat analysis, but the heroin group also showed a significantly greater group also showed a significantly greater response than the methadone group response than the methadone group (Table 2) . (Table 2) .
Using a more conservative analysis Using a more conservative analysis strategy that defined responders as only strategy that defined responders as only those patients responding on both primary those patients responding on both primary outcome measures, the intent-to-treat outcome measures, the intent-to-treat analysis showed a significantly greater reanalysis showed a significantly greater response rate in the heroin compared with sponse rate in the heroin compared with the methadone group (57.3% the methadone group (57.3% v.
v. 44.8% 44.8% OR OR¼1.67, 95% CI 1.30-2.14, 1.67, 95% CI 1.30-2.14, P P5 50.001). 0.001). Using this strategy analysis of the 546 parUsing this strategy analysis of the 546 participants completing the study also showed ticipants completing the study also showed a significantly better response rate for the a significantly better response rate for the heroin than the methadone group (63.6 heroin than the methadone group (63.6 v.
v. 39.5%, OR 39.5%, OR¼2.73, 95% CI 1.88-3.97, 2.73, 95% CI 1.88-3.97, P P5 50.001). 0.001).
Physical health (OTI Health Scale) Physical health (OTI Health Scale) showed a significant improvement in both showed a significant improvement in both groups, with the greatest improvement obgroups, with the greatest improvement observed during the time while preparing for served during the time while preparing for initiation of treatment and the first month initiation of treatment and the first month of treatment (Fig. 2) . The assessment of illiof treatment (Fig. 2) . The assessment of illicit drug use (according to self-reported cit drug use (according to self-reported data) showed a marked reduction of street data) showed a marked reduction of street heroin use in both groups, but a more proheroin use in both groups, but a more pronounced reduction in the heroin group, and nounced reduction in the heroin group, and a moderate reduction of cocaine use in both a moderate reduction of cocaine use in both groups (Fig. 3) . Urine testing at 6 and 12 groups (Fig. 3) . Urine testing at 6 and 12 months for street heroin, as well as weekly months for street heroin, as well as weekly urine testing for cocaine, confirms the selfurine testing for cocaine, confirms the selfreported data (Fig. 4) . Hair analysis for reported data (Fig. 4) . Hair analysis for cocaine use confirmed results of urine cocaine use confirmed results of urine testing and self-reported data, showing an testing and self-reported data, showing an overall decrease in cocaine use, but overall decrease in cocaine use, but especially a decrease in intensive use (from especially a decrease in intensive use (from 29.5 to 17.2% of samples in the heroin 29.5 to 17.2% of samples in the heroin group and 31.6 to 22.4% in the methadone group and 31.6 to 22.4% in the methadone group). group).
Safety Safety
A total of 315 serious adverse events were A total of 315 serious adverse events were reported during the 12-month study period: reported during the 12-month study period: 177 among 124 participants in the heroin 177 among 124 participants in the heroin group and 138 among 88 participants in group and 138 among 88 participants in the methadone group (Table 3 ). In 58 inthe methadone group (Table 3 ). In 58 instances (32.8%) in the heroin group, the stances (32.8%) in the heroin group, the adverse event was possibly, probably or deadverse event was possibly, probably or definitely related to the study medication, finitely related to the study medication, whereas in the methadone group this whereas in the methadone group this occurred less often (15 serious adverse occurred less often (15 serious adverse events, 10.9%). events, 10.9%).
Of the 58 adverse events possibly, probOf the 58 adverse events possibly, probably or definitely related to the heroin ably or definitely related to the heroin medication, 41 occurred within a few medication, 41 occurred within a few minutes of injection, 31 of these events minutes of injection, 31 of these events were related to respiratory depression, in were related to respiratory depression, in most cases associated with unreported most cases associated with unreported concomitant illicit benzodiazepine use, concomitant illicit benzodiazepine use, whereas 10 were related to an epileptic whereas 10 were related to an epileptic seizure. Considering the longer average seizure. Considering the longer average length of per-protocol treatment in the length of per-protocol treatment in the heroin compared with the methadone heroin compared with the methadone group (149 350 group (149 350 v.
v. 97 500 cumulative treat-97 500 cumulative treatment days), a serious adverse event that ment days), a serious adverse event that was possibly, probably or definitely related was possibly, probably or definitely related to the study medication occurred 2.5 times to the study medication occurred 2.5 times more often (every 2572 more often (every 2572 v.
v. 6501 treatment 6501 treatment days in the heroin and methadone groups days in the heroin and methadone groups respectively). There were 12 deaths (5 in respectively). There were 12 deaths (5 in heroin group, 7 in methadone group) in heroin group, 7 in methadone group) in the 12-month study period for the intentthe 12-month study period for the intentto-treat population. Of these only 5 to-treat population. Of these only 5 occurred while the participant was using occurred while the participant was using study medication and none were possibly, study medication and none were possibly, probably or definitely related to the study probably or definitely related to the study medication (3 in heroin group: 1 spleen medication (3 in heroin group: 1 spleen rupture after falling, 1 intoxication with rupture after falling, 1 intoxication with illicit methadone 1 owing to pneumonia illicit methadone 1 owing to pneumonia and myocarditis; 2 in methadone group: 1 and myocarditis; 2 in methadone group: 1 ruptured aneurysm, 1 reason unknown ruptured aneurysm, 1 reason unknown but no methadone in days before death). but no methadone in days before death).
DISCUSSION DISCUSSION
Main findings Main findings
This randomised controlled trial found that This randomised controlled trial found that heroin-assisted treatment of people with seheroin-assisted treatment of people with severe opioid dependence and treatment vere opioid dependence and treatment 5 9 5 9 AUTHOR'S PROOF AUTHOR'S PROOF Severity Index (GSI) of the Symptom Check-List (SCL^90^R) during the study period; ö Severity Index (GSI) of the Symptom Check-List (SCL^90^R) during the study period; ö^ö, heroin; ö, heroin; ö ö. .ö ö, methadone.The SCL^90^R was not administered at randomisation to avoid overlap artefacts, since the , methadone.The SCL^90^R was not administered at randomisation to avoid overlap artefacts, since the SCL^90^R measures symptoms occurring in the past 7 days. SCL^90^R measures symptoms occurring in the past 7 days.
resistance more effectively improved health resistance more effectively improved health and reduced illicit drug use than methadone and reduced illicit drug use than methadone maintenance treatment. The main effect of maintenance treatment. The main effect of heroin-assisted treatment on each primary heroin-assisted treatment on each primary outcome measure was seen within the first outcome measure was seen within the first few months of treatment, and became more few months of treatment, and became more pronounced over the following months, pronounced over the following months, thus indicating the necessity of long-term thus indicating the necessity of long-term treatment to increase health benefits. The treatment to increase health benefits. The high response rates in the methadone group high response rates in the methadone group indicate that a well-structured treatment indicate that a well-structured treatment with trained therapists using standardised with trained therapists using standardised and clinically relevant psychosocial interand clinically relevant psychosocial interventions can lead to positive outcomes even ventions can lead to positive outcomes even in a group that has previously responded in a group that has previously responded poorly to methadone treatment. The confirpoorly to methadone treatment. The confirmation of the positive results in the heroin mation of the positive results in the heroin group in the per-protocol analysis is of group in the per-protocol analysis is of importance because a positive outcome in importance because a positive outcome in the methadone group was expected owing the methadone group was expected owing to a low retention rate (highly selected to a low retention rate (highly selected group) but remained significantly below group) but remained significantly below the positive outcome in the heroin group. the positive outcome in the heroin group. These positive effects of heroin-assisted These positive effects of heroin-assisted treatment should be weighted against the treatment should be weighted against the higher rate of serious adverse events which higher rate of serious adverse events which appear to be associated with the route of appear to be associated with the route of administration of opioids and are not unexadministration of opioids and are not unexpected. However, the controlled clinical pected. However, the controlled clinical setting for heroin treatment, with a setting for heroin treatment, with a required 30 min stay after intravenous inrequired 30 min stay after intravenous injection, allows adverse events to be easily jection, allows adverse events to be easily managed clinically, unlike when street managed clinically, unlike when street heroin is injected in uncontrolled and unhyheroin is injected in uncontrolled and unhygienic settings. No fatalities occurred that gienic settings. No fatalities occurred that were possibly, probably or definitely rewere possibly, probably or definitely related to the study medication in either lated to the study medication in either group. The rate of serious adverse events group. The rate of serious adverse events was higher than in the Dutch study was higher than in the Dutch study (van den Brink (van den Brink et al et al, 2003) , which may be , 2003), which may be because in the latter study heroin-assisted because in the latter study heroin-assisted treatment was supplementary to methatreatment was supplementary to methadone maintenance treatment. done maintenance treatment.
This study confirms in a large sample This study confirms in a large sample the positive effects of heroin-assisted treatthe positive effects of heroin-assisted treatment reported from uncontrolled (Rehm ment reported from uncontrolled (Rehm et al et al, 2001 ) and controlled (Perneger , 2001 ) and controlled (Perneger et al et al, , 1998; van den Brink 1998; van den Brink et al et al, 2003) trials for , 2003) trials for people resistant to methadone treatment. people resistant to methadone treatment. These data also show that heroin-assisted These data also show that heroin-assisted treatment can be helpful for those with treatment can be helpful for those with heroin dependence currently not in treatheroin dependence currently not in treatment. It should be noted, however, that ment. It should be noted, however, that many of the latter group have an extensive many of the latter group have an extensive treatment history and their baseline charactreatment history and their baseline characteristics were similar to the methadone teristics were similar to the methadone patients. The use of two structured psychopatients. The use of two structured psychosocial interventions in each treatment social interventions in each treatment condition suggests that the observed differcondition suggests that the observed differences between the methadone and heroin ences between the methadone and heroin groups were not the result of differences groups were not the result of differences in psychosocial treatment. in psychosocial treatment.
Another methodological strength of the Another methodological strength of the study is the conservative analysis strategy, study is the conservative analysis strategy, using a worst case strategy for all missing using a worst case strategy for all missing data not replaced by LOCF. Considering data not replaced by LOCF. Considering the nature of this group of patients, the the nature of this group of patients, the high rate of adherence, with 12-month data high rate of adherence, with 12-month data for most participants, strengthens the for most participants, strengthens the interpretation of the results. Despite a interpretation of the results. Despite a general preference for other methods such general preference for other methods such as direct likelihood analysis or multiple as direct likelihood analysis or multiple imputation for missing data, in this study imputation for missing data, in this study these methods would have reproduced difthese methods would have reproduced differences in distribution of missing values, ferences in distribution of missing values, whereas the LOCF procedure allowed only whereas the LOCF procedure allowed only data collected after 6 months to replace data collected after 6 months to replace missing data and mirrors more actual treatmissing data and mirrors more actual treatment effects. Considering the high drop-out ment effects. Considering the high drop-out rate in the methadone group, a LOCF rate in the methadone group, a LOCF 6 0 6 0 AUTHOR'S PROOF AUTHOR'S PROOF Table 3  Table 3 Serious adverse events in intent-to-treat population during 12-month study period Serious adverse events in intent-to-treat population during 12-month study period .ö ö, methadone; self-reported data were collected by the attending physician, whenever possible missing , methadone; self-reported data were collected by the attending physician, whenever possible missing values were completed with data from independent interviews. values were completed with data from independent interviews. , methadone.
procedure leads to more results of patients procedure leads to more results of patients still in treatment, therefore favouring the still in treatment, therefore favouring the overall results of the methadone group. overall results of the methadone group.
Limitations of the study Limitations of the study
Given the nature of the medication under Given the nature of the medication under study, a double-blind design was not study, a double-blind design was not possible (Bammer possible (Bammer et al et al, 1999) . Further-, 1999) . Furthermore, the response rates for the primary more, the response rates for the primary outcome measure 'health' were much highoutcome measure 'health' were much higher for both groups than expected, so that er for both groups than expected, so that the extent of improvement defined as a rethe extent of improvement defined as a response may have been too low. Therefore, sponse may have been too low. Therefore, a sensitivity analysis using the worst case a sensitivity analysis using the worst case strategy and a 40% improvement as a defistrategy and a 40% improvement as a definition of response was performed, in order nition of response was performed, in order to better compare the results with the to better compare the results with the Dutch study (van den Brink Dutch study (van den Brink et al et al, 2003) . , 2003) . This showed that lower response rates were This showed that lower response rates were observed, but the response rate for the observed, but the response rate for the heroin group remained significantly higher heroin group remained significantly higher than that for the methadone group than that for the methadone group The analysis with a single response criterion -those participants reresponse criterion -those participants responding on both primary outcome sponding on both primary outcome measures -allows for an easier comparison measures -allows for an easier comparison with and confirmation of the Dutch results. with and confirmation of the Dutch results. However, the analysis of separate response However, the analysis of separate response criteria has the advantage of allowing a criteria has the advantage of allowing a more differentiated analysis of effects. more differentiated analysis of effects.
Another aspect that needs to be disAnother aspect that needs to be discussed is the improvement in the month cussed is the improvement in the month between baseline and initiation of treatbetween baseline and initiation of treatment with study medication, especially ment with study medication, especially with respect to physical health. This imwith respect to physical health. This improvement is probably the result of a provement is probably the result of a combination of regression to the mean combination of regression to the mean and treatment between baseline assessment and treatment between baseline assessment and randomisation. Considering the very and randomisation. Considering the very poor health status of the sample at baseline, poor health status of the sample at baseline, for ethical reasons physical and/or mental for ethical reasons physical and/or mental health problems had to be attended to even health problems had to be attended to even before initiation of study treatment. before initiation of study treatment. However, since randomisation took place However, since randomisation took place thereafter, treatment prior to randomisthereafter, treatment prior to randomisation and possible improvements do not ation and possible improvements do not bias the observed differences between the bias the observed differences between the two medication conditions (heroin or two medication conditions (heroin or methadone) after 12 months' treatment. methadone) after 12 months' treatment. None the less, if the response criteria for None the less, if the response criteria for physical health were defined using the physical health were defined using the OTI score at initiation of treatment as the OTI score at initiation of treatment as the baseline, 77.1% of the heroin group and baseline, 77.1% of the heroin group and 69.2% of the methadone group would have 69.2% of the methadone group would have been defined as responders for the primary been defined as responders for the primary outcome measure 'health', with a signifioutcome measure 'health', with a significant difference (OR cant difference (OR¼1.50, 95% CI 1.13-1.50, 95% CI 1.13-1.99, 1.99, P P¼0.005). 0.005). The rather low retention rate in the The rather low retention rate in the methadone group could be considered a methadone group could be considered a further limitation. The high drop-out rate further limitation. The high drop-out rate in the methadone group is probably a result in the methadone group is probably a result of the disappointment at not being randomof the disappointment at not being randomised into the heroin group. However, a ised into the heroin group. However, a large portion of those dropping-out took large portion of those dropping-out took up other treatments, so that the limiting up other treatments, so that the limiting effect of the low retention rate is minimised effect of the low retention rate is minimised in a randomised intent-to-treat analysis. in a randomised intent-to-treat analysis.
A final limitation is that not all data on A final limitation is that not all data on illicit drug use were based on objective illicit drug use were based on objective urine or hair analysis, self-reported data urine or hair analysis, self-reported data were also included. However, studies have were also included. However, studies have shown self-reported data to be accurate, shown self-reported data to be accurate, reliable and valid, provided that confidentireliable and valid, provided that confidentiality is ensured and no sanctions are conality is ensured and no sanctions are connected to the answers (Rounsaville, 1993) . nected to the answers (Rounsaville, 1993) . (Ferri et al et al, 2005) by providing strong further evi-, 2005) by providing strong further evidence of the efficacy of prescribed heroin in dence of the efficacy of prescribed heroin in the treatment of people with opioid depenthe treatment of people with opioid dependence who have not profited from other dence who have not profited from other forms of treatment. Considering the higher forms of treatment. Considering the higher rate of serious adverse events, heroin prerate of serious adverse events, heroin prescription should remain a treatment of last scription should remain a treatment of last resort for people who are currently or have resort for people who are currently or have in the past failed at maintenance treatment. in the past failed at maintenance treatment.
Implications Implications
